TONIX PHA.NEW2023 DL-,001
TONIX PHA.NEW2023 DL-,001
Aktie · US8902608541 · TNXP · A3EDH2 (XNCM)
Übersicht Finanzkennzahlen
35,20 EUR
4,18 % 1,41 EUR
Frankfurt (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 23:59

Aktuelle Kurse von TONIX PHA.NEW2023 DL-,001

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
TNXP
USD
06.06.2025 23:59
40,10 USD
38,39 USD
+4,45 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
-0,49 % 1,13 % 107,16 % 197,36 % 102,88 % -88,58 % -99,99 %

Firmenprofil zu TONIX PHA.NEW2023 DL-,001 Aktie

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Unternehmensdaten

Name TONIX PHA.NEW2023 DL-,001
Firma Tonix Pharmaceuticals Holding Corp.
Symbol TNXP
Website https://www.tonixpharma.com
Heimatbörse XNCM Frankfurt
WKN A3EDH2
ISIN US8902608541
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Seth Lederman M.D.
Marktkapitalisierung 111 Mio
Land Vereinigte Staaten von Amerika
Währung EUR
Mitarbeiter 0,1 T
Adresse 26 Main Street, 07928 Chatham
IPO Datum 2012-05-10

Aktien-Splits

Datum Split
05.02.2025 1:100

Ticker Symbole

Name Symbol
NASDAQ TNXP

Weitere Aktien

Investoren die TONIX PHA.NEW2023 DL-,001 die halten, haben auch folgende Aktien im Depot:
AMUNDI FUNDS GLOBAL INFLATION BOND - M2 EUR (C)
AMUNDI FUNDS GLOBAL INFLATION BOND - M2 EUR (C) ETF
CASIO COMPUTER
CASIO COMPUTER Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025